Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe
MWN-AI** Summary
Insulet Corporation (NASDAQ: PODD) has expanded its reach in the European market by launching the innovative Omnipod® 5 Automated Insulin Delivery (AID) System in five additional countries: Italy, Denmark, Finland, Norway, and Sweden. The Omnipod 5 is uniquely designed for individuals aged two and older with type 1 diabetes and is the first tubeless AID system that supports compatibility with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (CGM) sensors.
Patrick Crannell, Insulet’s Senior Vice President and International General Manager, expressed excitement over this expansion, building on the successful introduction of the Omnipod 5 in other countries, including the UK, Germany, Netherlands, and France. Omnipod has distinguished itself as the leading insulin pump choice among new users in Europe, and the system’s first U.S. introduction in 2022 resulted in favorable clinical outcomes, illustrated by lower A1c levels and improved time in glucose range.
The integration of both sensor options offers users and healthcare providers greater flexibility in managing diabetes, allowing for an easier initiation of AID therapy. This feature is anticipated to greatly benefit individuals living with type 1 diabetes, as noted by Dr. Peter Adolfsson from Högsbo Hospital in Sweden, who highlighted the significant life changes the Omnipod 5 could facilitate.
Lina, a long-term diabetes sufferer from Sweden, shared her anticipation of using the Omnipod 5, emphasizing how the tubeless and waterproof design may simplify her active lifestyle. With the Omnipod 5, Insulet is positioning itself at the forefront of diabetes management innovation in Europe, aiming to enhance quality of life for many.
MWN-AI** Analysis
Insulet Corporation (NASDAQ: PODD) is strategically expanding its presence in the European market with the launch of its Omnipod® 5 Automated Insulin Delivery System in five new countries: Italy, Denmark, Finland, Norway, and Sweden. This expansion follows successful launches in other major European markets and positions Insulet favorably in the growing diabetes management sector.
The Omnipod 5 stands out due to its robust integration with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 continuous glucose monitoring systems, which enhances the flexibility for healthcare providers and patients. This capability is likely to drive adoption, particularly among individuals aged two years and older with type 1 diabetes, providing an attractive proposition for new users seeking advanced diabetes management solutions.
From a market perspective, it's important to note that Insulet commands a leading position as the preferred insulin pump among new users across Europe, which may translate into a sustained market share growth. The favorable responses from both patients and healthcare professionals highlight the system’s use case in simplifying life for individuals managing diabetes, thus solidifying Insulet’s brand reputation and fostering long-term customer loyalty.
Investors should consider the recent positive clinical outcomes attributed to Omnipod 5, particularly those showcasing improved A1c levels and reduced hypoglycemic events. This data could bolster healthcare provider recommendations, leading to increased prescriptions and a widening customer base.
Additionally, the upgraded compatibility with two dominant CGM devices should yield a comprehensive marketing strategy that accentuates the versatility of Omnipod 5. The innovative and user-friendly design — particularly its tubeless and waterproof features — addresses common patient concerns, enhancing its market appeal.
In conclusion, Insulet represents a compelling investment opportunity within the medical device sector, especially as it continues to carve out its niche in the diabetes care market. Investors should closely monitor sales figures following this recent expansion, as they will be indicative of Omnipod 5's success in a competitive landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
The Omnipod 5 Automated Insulin Delivery System is now commercially available in Italy, Denmark, Finland, Norway, and Sweden with Abbott’s FreeStyle Libre 2 Plus and Dexcom G6
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the Omnipod 5 Automated Insulin Delivery System is now commercially available in five more countries—Italy, Denmark, Finland, Norway, and Sweden.
Omnipod 5 is now available with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (CGM) sensor compatibility. Indicated for individuals aged two years and older with type 1 diabetes, Omnipod 5 is the first and only tubeless automated insulin delivery (AID) system integrated with both leading CGM sensor brands.
“We are excited to bring our flagship Omnipod 5 AID System to more people across Europe,” said Patrick Crannell, Insulet Senior Vice President and International General Manager. “Following our successful launches of Omnipod 5 in the U.K., Germany, Netherlands, and France, today’s announcement marks another significant step forward to help improve the lives of people with diabetes around the world.”
Omnipod is recognized as the number one insulin pump for new pump users in Europe 1 . Omnipod 5 is also the number one prescribed AID system in the U.S. 2 and the first tubeless, waterproof 3 AID system with proactive glucose control designed to deliver exceptional ease of use. It was first introduced in the U.S. in 2022, integrated with Dexcom G6, and has demonstrated strong clinical results with real world evidence including lower A1c and improved time in range, while maintaining low time in hypoglycemia. 4,5,6
"I can’t wait to get my Omnipod 5 so I can think less about diabetes,” said Lina, a 45-year-old resident of Sweden who has lived with type 1 diabetes for over 20 years. “I had to inject insulin multiple times per day for many years, but I have also been using a tubed insulin pump. Now that Omnipod 5 is available, I am excited to see what difference a tubeless and waterproof AID system will make when doing sports, wearing nice dresses, and skiing. My worry and stress that comes with managing this chronic condition will hopefully lessen, and my active life with diabetes may become simpler.”
Sensor integration with Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 allows many users to benefit from Omnipod 5 with their sensor of choice. It also gives prescribers more flexibility when recommending a sensor for their patients, making it fast and easy to start AID therapy with Omnipod 5.
“Omnipod 5 with two sensor choices is going to change lives for people living with type 1 diabetes in Italy and throughout the Nordics. The significant benefits of Omnipod 5, which is transforming diabetes therapy already in other countries, is beyond exciting and welcomed news for so many people with type 1 diabetes who require daily insulin to live,” said Dr. Peter Adolfsson, a Senior Physician, MD and pediatrician at the Högsbo Hospital in Sweden.
To learn more or to get started, visit the Omnipod website .
1 Omnipod was the most frequently chosen pump in the past year among people new to an insulin pump in a survey conducted by dQ&A across Germany, Italy, France, United Kingdom, Spain, Netherlands, Sweden. N=3646; 1H'24: P.47 (August 2024).
2 USA 2023, Data on file.
3 The Pod has an IP28 rating for up to 7.6 meters (25 feet) for 60 minutes. The Omnipod ® 5 controller is not waterproof. The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under 2.4 meters (8 feet) of water for up to 24 hours without failure when properly installed. The FreeStyle Libre 2 Plus sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.
4 Sherr JL, et al. Diabetes Care (2022). Study in 80 people with type 1 diabetes (T1D) aged 2 - 5.9 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.
5 Brown et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.
6 Forlenza GP et al. Diabetes Technology & Therapeutics (2024). Real-World Evidence of Omnipod 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit Insulet.com or omnipod.com .
©2025 Insulet Corporation. Omnipod and Podder are registered trademarks of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113217259/en/
Investor Relations:
June Lazaroff
Senior Director, Investor Relations
(978) 600-7718
jlazaroff@insulet.com
Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com
FAQ**
How does the expansion of Omnipod 5 in Italy, Denmark, Finland, Norway, and Sweden impact Insulet Corporation PODD's market share in the European automated insulin delivery sector?
What are the projected sales growth figures for Insulet Corporation PODD following the introduction of Omnipod 5 in these new countries?
How does the integration of Abbott's FreeStyle Libre 2 Plus and Dexcom G6 enhance the competitive advantage for Insulet Corporation PODD in the diabetes management market?
With the positive clinical results associated with Omnipod 5, how does Insulet Corporation PODD plan to leverage real-world evidence to attract more users and health providers?
**MWN-AI FAQ is based on asking OpenAI questions about Insulet Corporation (NASDAQ: PODD).
NASDAQ: PODD
PODD Trading
3.84% G/L:
$226.18 Last:
87,045 Volume:
$222.80 Open:
